Arcutis Biotherapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Arcutis is a commercial-stage biopharmaceutical company developing and selling dermatology treatments. Its commercial products are ZORYVE cream for plaque psoriasis and ZORYVE foam for seborrheic dermatitis.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Total revenue | $49.6 million | $2.8 million |
| Product revenue | $21.6 million | $2.8 million |
| Net loss | $35.4 million | $80.1 million |
| Operating cash used | $31.6 million | $80.3 million |
| Cash, cash equivalents, restricted cash and marketable securities | $404.5 million | $272.8 million at Dec. 31, 2023 |
| Long-term debt, net | $202.8 million | $201.8 million at Dec. 31, 2023 |
Product revenue comprised $15.0 million from ZORYVE cream and $6.5 million from ZORYVE foam. Other revenue was $28.0 million: a $25.0 million Sato upfront payment and a $3.0 million Huadong development and regulatory milestone. Cost of sales was $3.3 million; the filing notes that some inventory costs had previously been expensed as research and development, so current cost of sales reflects a lower average unit cost expected to continue for about 18 months. The filing does not provide a directly comparable normalized product gross margin.
Operating expenses were $81.2 million, including $23.1 million of research and development and $54.8 million of selling, general and administrative expense. Operating loss was $31.6 million; interest expense was $7.5 million and other income was $4.0 million. Loss per share was $0.32, versus $1.31 a year earlier.
Cash, cash equivalents and restricted cash increased by $101.4 million during the quarter, primarily reflecting $161.7 million of net proceeds from a February public stock offering, partly offset by operating cash use and net purchases of marketable securities. The offering issued 18.2 million shares, net of issuance costs. Stockholders’ equity was $224.9 million at quarter-end.
The company had $200.0 million of principal debt outstanding, bearing a floating rate of 12.87% at March 31, with a January 1, 2027 maturity. The company reports a $213.9 million principal-and-final-fee payment due at maturity. A 100-basis-point interest-rate increase would add approximately $2.0 million in annual interest expense, before offsets from investment income. Debt is secured by substantially all assets, including intellectual property.
Material changes from the comparable period
- Total revenue rose $46.8 million, primarily due to higher ZORYVE cream sales, the January 2024 foam launch, and the Sato and Huadong license payments.
- Research and development expense declined $12.2 million, largely following completion of Phase 3 studies; SG&A increased $11.9 million as commercialization spending grew.
- Net loss narrowed by $44.7 million. This comparison includes $28.0 million of licensing and milestone revenue in Q1 2024.
- Cash and marketable securities rose from $272.8 million at year-end, with the increase supported principally by equity financing. Shares issued and outstanding increased from 96.8 million at year-end to 115.5 million at March 31.
Outlook, risks and unusual items
- Management expects continued operating losses and significant commercialization and development spending. It believes existing capital resources are sufficient for projected operating requirements for at least 12 months from issuance of the financial statements; additional financing may nevertheless be needed, and availability on acceptable terms is not assured.
- Management’s stated development plans include an FDA target action date of July 7, 2024 for the ZORYVE cream atopic dermatitis application for patients aged 6 and older; a planned Q3 2024 submission for foam in scalp and body psoriasis; and a potential subsequent cream application for children aged 2–5, contingent on approval of the existing application. These are plans, not assurances of regulatory outcomes.
- The Sato agreement grants Japan rights and generated a $25.0 million upfront payment; it also provides for potential regulatory and sales milestones and royalties. Huadong’s territories include Greater China and Southeast Asia; its agreement provides for potential further milestones and royalties. Future milestone and royalty receipts are contingent and not assured.
- The company says it met its debt agreement’s minimum financing covenant during Q1 and was in compliance with all loan covenants at March 31. The loan also includes minimum product-revenue requirements, restrictions and events of default; a default could accelerate repayment and raise the interest rate.
- Arcutis sued Padagis in March 2024 over an ANDA seeking approval for a generic ZORYVE cream. Padagis denied infringement and counterclaimed that the asserted patents are not infringed, invalid and/or unenforceable. The outcome and commercial impact are uncertain.
- The company relies on third parties, including some single-source suppliers, for manufacturing and clinical-trial materials and has no internal manufacturing capability. It also identifies financing, product commercialization, regulatory, clinical-development, and interest-rate risks. No material changes to the prior annual-report risk factors were reported.
- A stock-option exchange resulted in cancellation of options covering about 5.1 million shares and issuance of about 2.1 million replacement RSUs; the modification requires $8.6 million of incremental compensation expense over the replacement awards’ service periods.
Important facts for investors to verify
- Whether ZORYVE cream and foam sales growth continues, and how sales deductions, access and commercialization costs affect net revenue and cash use.
- Progress and FDA decisions on the atopic dermatitis and scalp/body psoriasis applications, as well as development progress for ARQ-255 and ARQ-234.
- Cash runway against ongoing operating losses, the timing and terms of any additional financing, and compliance with monthly product-revenue covenants.
- Debt service and maturity obligations, including the floating-rate exposure, final fee and collateral provisions.
- Developments in the Padagis patent litigation and any effect on ZORYVE’s market protection.
- Whether licensing milestones and royalties are achieved; current-quarter license revenue should not be assumed to recur at the same level.